The Laboratoire Ethnodyne

Publications & Patents

The Ethnodyne company is already holding very well and has a portfolio of 8 patents.
1 publication and 1 process patent with claims in the field of angiogenesis and more particularly for :

- Oncology,

- Treatment of the Age-Related Macula Degeneration (ARMD): Journal of Medicinal Food

4 patents of composition in the field of Neurodegenerative diseases and more particularly for an application in the treatment of :

- Parkinson's disease: WO2016 166565 A1

- Alzheimer's disease: WO2106 150481 A1

- Neuromuscular diseases (Amyotrophic Lateral Sclerosis),

- Other pathologies related to demyelination (Multiple Sclerosis).

3 patents for new molecules in the field of Neurodegenerative diseases and more particularly Alzheimer's disease and Parkinson's disease.

ongoing clinical study

The Ethnodyne laboratory is conducting a pilot clinical study (ETHNOPARK) at the University Hospital of Strasbourg in the Neurology department (pathology of movement) to evaluate the effectiveness of a composition of Parkinson's disease and associated disorders.

The results of the study are expected for the first quarter of 2019.

The laboratory Ethnodyne has developed and markets a range of 5 food supplements: